Gabapentin for Neuropathic Pain Management

Introduction to Gabapentin

Gabapentin is effective for painful diabetic neuropathy at doses typically up to 3600 mg/day, though doses prescribed in clinical practice are often lower 1
The American Geriatrics Society recommends starting with lowest doses (100-200 mg/day) for older adults due to increased risk of somnolence, dizziness, and mental clouding 2

The American Geriatrics Society supports trials of gabapentinoids (gabapentin and pregabalin) for muscle pain associated with fibromyalgia when severe enough to interfere with quality of life 2
Gabapentin is recommended as first-line oral pharmacological treatment for chronic HIV-associated neuropathic pain 3, 4, 5
Gabapentin may be considered as a second-line treatment for central poststroke pain when first-line agents (amitriptyline, lamotrigine) fail 6

The Journal of the American Geriatrics Society suggests that doses in clinical practice are often lower than those used in trials (which used up to 3600 mg/day), potentially leading to suboptimal efficacy 2
For renal impairment, the Journal of the American Geriatrics Society recommends using lowest starting doses (100-200 mg/day) and adjusting based on creatinine clearance 2

Gabapentin binds to the α2δ-1 subunit of voltage-gated calcium channels, reducing calcium influx and decreasing synaptic neurotransmitter release into hyperexcited neurons 1

The Journal of the American Geriatrics Society reports that the most common adverse effects of gabapentin are somnolence, dizziness, mental clouding, which can be particularly problematic in older patients 2
The British Journal of Pharmacology notes that gabapentin has a low toxicity profile, making it attractive for various patient groups including the elderly 7

The American College of Cardiology is not mentioned in this article, however, the Clinical Infectious Diseases guideline recommends gabapentin as first-line oral pharmacological treatment for chronic HIV-associated neuropathic pain 8
The Mayo Clinic Proceedings reports that all 16 patients in one survey showed improvement with gabapentin for HIV-associated neuropathic pain, and also for erythromelalgia, though sedation and lower extremity edema may limit benefits 9

The Mayo Clinic Proceedings suggests that a maximum dose of 3600 mg daily may be needed in some patients 9

The Mayo Clinic Proceedings reports that 7% of patients experience peripheral edema, which may counteract benefits of topical treatments in erythromelalgia 9